罗欣药业(002793.SZ)：预计2025年度净亏损2.5亿元-3.4亿元

Core Viewpoint - Luoxin Pharmaceutical (002793.SZ) forecasts a net loss of 250 million to 340 million yuan for the year 2025, compared to a loss of 965.4962 million yuan in the previous year [1] Financial Performance - The company anticipates a non-GAAP net loss of 260 million to 350 million yuan for 2025, compared to a loss of 768.1208 million yuan in the same period last year [1] Strategic Focus - In 2025, the company will continue to strategically focus on the pharmaceutical manufacturing sector, particularly in the advantageous digestive system field [1] - The growth of the company's core innovative drug, Tegoprazan (brand name: Taixinzan®), is expected to drive improvements in product structure and growth quality [1]